GlassScriptPhysician profile
John T Livecchi
NPI 1669434270
$3,317.52
in general payments reported to CMS, 2019-2025
17 companies · $963 in 2025
The $963 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,139 · 2020: $61.52 · 2022: $456 · 2023: $242 · 2024: $456 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,660.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $528.20 | 2019-2024 | Luxor, Ngenuity |
| Biotissue Holdings INC. | $355.75 | 2019-2020 | |
| Lumenis Be INC | $321.46 | 2025 | M22 |
| Glaukos Corporation | $309.63 | 2025 | Idosetr |
| Mallinckrodt Enterprises LLC | $237.61 | 2019 | |
| Ocular Therapeutix, INC. | $219.31 | 2022-2025 | Dextenza |
| Horizon Therapeutics Plc | $216.89 | 2022-2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $158.49 | 2019 | |
| Apellis Pharmaceuticals, INC. | $142.56 | 2023-2025 | Syfovre |
| Harrow Eye, LLC | $123.90 | 2024 | Flarex, Verkazia, Iheezo |
| Amgen INC. | $110.92 | 2024 | Tepezza |
| Dompe US, INC. | $108.54 | 2025 | Oxervate |
| Regeneron Healthcare Solutions, INC. | $107.95 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $102.65 | 2024 | Tecnis Simplicity |
| Genentech USA, INC. | $99.30 | 2023 | Vabysmo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $96.92 | 2019 | |
| Sight Sciences, INC. | $77.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Livecchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.